• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·006280.KS
Share

GC Biopharma Corp. Stocks

₩ 127900Last Updated 07.08.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

₩ 912.72M

₩ 127900
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

GC Biopharma Corp. is a pharmaceutical enterprise primarily involved in the production and distribution of various medical products. Its extensive portfolio encompasses specialized treatments for blood-related conditions, non-prescription remedies, general medications, and immunizations, among other therapeutic solutions. The company was established on November 1, 1969, and its principal corporate offices are situated in Yongin, South Korea.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 006280.KS is 205779 and suggests 58.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 19:49

Berkshire Hathaway has reduced its "cash cushion" for the first time in four years

08.08.2026 16:01

Small-Cap Highlights: SolarEdge Forecast, Bitdeer's $4.7 Billion Deal, Replimune's Success

08.08.2026 13:01

A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026